Kenvue’s stock jumps on Starboard Value stake news; Lilly continues to sue copycat weight-loss drug distributors; J&J’s ketamine-derived drug takes off.
Five things for pharma marketers to know for Monday morning
GLP-1 drugs could help people struggling with addiction; CVS names new CEO as financial problems continue; Consumer groups press FTC to block Novo-Catalent deal.
PAI Partners to raise offer for Sanofi’s consumer unit; Lilly’s CSO warns of politicians weakening patents; PE firms pull back from investing in consumer companies due to GLP-1 boom.
Five things for pharma marketers to know for Thursday morning
McKinsey nears $500 million opioids settlement; FDA places clinical hold on Novavax’ investigational COVID/flu vaccine; Neurogastrx released data showing its drug could help reduce nausea and vomiting associated with GLP-1s.
Five things for pharma marketers to know for Wednesday morning
Walgreens to shudder 1,200 stores; Sacklers gear up for bankruptcy legal battle; Lilly inks collaboration with U.K. to examine impact of GLP-1s on unemployment.
MM+M/Publicis Health Pharma Marketing Transformation Survey shows innovation is beginning to take hold